Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility- weighted contrast-enhanced perfusion MR imaging

Radiology

Volumn 253, Issue 2, 2009, Pages 486-496

  Barajas Jr , Ramon F ^a   Chang, Jamie S ^a   Segal, Mark R ^a   Parsa, Andrew T ^a   McDermott, Michael W ^a   Berger, Mitchel S ^a   Cha, Soonmee ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; BRAIN CIRCULATION; CANCER SURGERY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GLIOBLASTOMA; HUMAN; INSTITUTIONAL REVIEW; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PH; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION DOSE; RADIATION FIELD; RADIATION NECROSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STUDENT T TEST;

BLOOD VOLUME; BRAIN; BRAIN NEOPLASMS; CEREBROVASCULAR CIRCULATION; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLIOBLASTOMA; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; NECROSIS; NEOPLASM RECURRENCE, LOCAL; RADIATION INJURIES; RADIOTHERAPY DOSAGE; SENSITIVITY AND SPECIFICITY;

EID: 76749097367     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2532090007     Document Type: Article

References (57)

1. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377-384.
2. Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007;5:894-915.
3. Fiveash JB, Spencer SA. Role of radiation therapy and radiosurgery in glioblastoma multiforme. Cancer J 2003;9:222-229.
4. Curnes JT, Laster DW, Ball MR, Moody DM, Witcofski RL. MRI of radiation injury to the brain. AJR Am J Roentgenol 1986;147:119-124.
5. Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH. Brain radiation lesions: MR imaging. Radiology 1986;158:149-155.
6. Hohwieler ML, Lo TC, Silverman ML, Freidberg SR. Brain necrosis after radiotherapy for primary intracerebral tumor. Neurosurgery 1986;18:67-74.
7. Lupo JM, Cha S, Chang SM, Nelson SJ. Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity. AJNR Am J Neuroradiol 2005;26:1446-1454.
8. Cha S, Lu S, Johnson G, Knopp EA. Dynamic susceptibility contrast MR imaging: correlation of signal intensity changes with cerebral blood volume measurements. J Magn Reson Imaging 2000;11:114-119.
9. Hu LS, Baxter LC, Smith KA, et al. Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements. AJNR Am J Neuroradiol 2009;30:552-558.
10. Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.
11. Knopp EA, Cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791-798.
12. Cha S, Lupo JM, Chen MH, et al. Differentiation of glioblastoma multiforme and single brain metastasis by peak height and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2007;28:1078-1084.
13. Barajas RF, Chang JS, Sneed PK, Segal MR, McDermott MW, Cha S. Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2009;30:367-372.
14. Maia AC Jr, Malheiros SM, da Rocha AJ, et al. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol 2005;26:777-783.
15. Sadeghi N, D'Haene N, Decaestecker C, et al. Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 2008;29:476-482.
16. Barajas R, Chang J, Hodgson G, et al. Characterization of GBM cellular and molecular biology with DSC perfusion MR imaging [abstr]. In: American Society of Neuroradiology annual meeting program. Oak Brook, Ill: American Society of Neuroradiology, 2009.
17. Paulson ES, Schmainda KM. Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors. Radiology 2008;249:601-613.
18. Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249-265.
19. Belliveau JW, Rosen BR, Kantor HL, et al. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med 1990;14:538-546.
20. Maeda M, Itoh S, Kimura H, et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993;189:233-238.
21. Cha S. Perfusion imaging of brain tumors. Top Magn Reson Imaging 2004;15:279-289.
22. Bruening R, Kwong KK, Vevea MJ, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol 1996;17:831-840.
23. Levin JM, Wald LL, Kaufman MJ, Ross MH, Maas LC, Renshaw PF. T1 effects in sequential dynamic susceptibility contrast experiments. J Magn Reson 1998;130:292-295.
24. Runge VM, Kirsch JE, Wells JW, Dunworth JN, Hilaire L, Woolfolk CE. Repeat cerebral blood volume assessment with first-pass MR imaging. J Magn Reson Imaging 1994;4:457-461.
25. Levin JM, Wald LL, Kaufman MJ, Ross MH, Maas LC, Renshaw PF. Sequential dynamic susceptibility contrast MR experiments in human brain: residual contrast agent effect, steady state, and hemodynamic perturbation. Magn Reson Med 1995;34:655-663.
26. Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont, Calif: Wadsworth, 1984;
27. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2006.
28. Babu R, Huang PP, Epstein F, Budzilovich GN. Late radiation necrosis of the brain: case report. J Neurooncol 1993;17:37-42.
29. Morris JG, Grattan-Smith P, Panegyres PK, O'Neill P, Soo YS, Langlands AO. Delayed cerebral radiation necrosis. Q J Med 1994;119-129.
30. Hopewell JW, Calvo W, Jaenke R, Reinhold HS, Robbins ME, Whitehouse EM. Microvasculature and radiation damage. Recent Results Cancer Res 1993;130:1-16.
31. Wesseling P, Ruiter DJ, Burger PC. Angiogenesis in brain tumors: pathobiological and clinical aspects. J Neurooncol 1997;32:253-265.
32. Oh BC, Pagnini PG, Wang MY, et al. Stereotactic radiosurgery: adjacent tissue injury and response after high-dose single fraction radiation. I. Histology, imaging, and molecular events. Neurosurgery 2007;60:31-45.
33. Sugahara T, Korogi Y, Kochi M, et al. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol 1998;171:1479-1486.
34. Earnest F 4th, Kelly PJ, Scheithauer BW, et al. Cerebral astroycytomas: histopahtologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988;166:823-827.
35. Le Bihan D, Douek P, Argyropoulou M, Turner R, Patronas N, Fulham M. Diffusion and perfusion magnetic resonance imaging in brain tumors. Top Magn Reson Imaging 1993;5:25-31.
36. Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21:881-890.
37. Sugahara T, Korogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901-909.
38. Spiegelmann R, Friedman WA, Bova FJ, Theele DP, Mickle JP. LINAC radiosurgery: an animal model. J Neurosurg 1993;78:638-644.
39. Heiland S, Benner T, Debus J, Rempp K, Reith W, Sartor K. Simultaneous assessment of cerebral hemodynamics and contrast agent uptake in lesions with disrupted blood-brain-barrier. Magn Reson Imaging 1999;17:21-27.
40. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859-867.
41. Uematsu H, Maeda M, Sadato N, et al. Measurement of the vascularity and vascular leakage of gliomas by double-echo dynamic magnetic resonance imaging: a preliminary study. Invest Radiol 2002;37:571-576.
42. Hazle JD, Jackson EF, Schomer DF, Leeds NE. Dynamic imaging of intracranial lesions using fast spin-echo imaging: differentiation of brain tumors and treatment effects. J Magn Reson Imaging 1997;7:1084-1093.
43. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. Magn Reson Med 1991;17:357-367.
44. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232.
45. Buckley DL. Uncertainty in the analysis of tracer kinetics using dynamic contrast-enhanced T1-weighted MRI. Magn Reson Med 2002;47:601-606.
46. Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2003;17:509-520.
47. Evelhoch JL. Key factors in the acquisition of contrast kinetic data for oncology. J Magn Reson Imaging 1999;10:254-259.
48. Taylor JS, Tofts PS, Port R, et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 1999;10:903-907.
49. Di Chiro G, Oldfield E, Wright DC, et al. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol 1988;150:189-197.
50. Olivero WC, Dulebohn SC, Lister JR. The use of PET in evaluating patients with primary brain tumours: is it useful? J Neurol Neurosurg Psychiatry 1995;58:250-252.
51. Chuang CF, Chan AA, Larson D, et al. Potential value of MR spectroscopic imaging for the radiosurgical management of patients with recurrent high-grade gliomas. Technol Cancer Res Treat 2007;6:375-382.
52. Wald LL, Nelson SJ, Day MR, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997;87:525-534.
53. Weybright P, Sundgren P, Maly P, et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 2005;185:1471-1476.
54. Schlemmer HP, Bachert P, Herfarth KK, Zuna I, Debus J, van Kaick G. Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy. AJNR Am J Neuroradiol 2001;22:1316-1324.
55. Kamada K, Houkin K, Abe H, Sawamura Y, Kashiwaba T. Differentiation of cerebral radiation necrosis from tumor recurrence by proton magnetic resonance spectroscopy. Neurol Med Chir (Tokyo) 1997;37:250-256.
56. Rock JP, Hearshen D, Scarpace L, et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002;51:912-919.
57. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001;22:604-612.